We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » New Black Box Warning for BMS Hepatitis B Drug
New Black Box Warning for BMS Hepatitis B Drug
August 24, 2007
Bristol-Myers Squibb (BMS) has agreed to include a new black box warning on the labeling for Baraclude, stating that the hepatitis B virus (HBV) drug is not recommended for patients who are co-infected with HIV/HBV and are not receiving highly active antiretroviral therapy due to the potential for the development of HIV resistance.